Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$0.47 USD
+0.06 (14.68%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $0.46 -0.01 (-2.65%) 6:28 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALGS 0.47 +0.06(14.68%)
Will ALGS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALGS
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
Other News for ALGS
Aligos Therapeutics Shareholders Back Key Corporate Resolutions
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Moderna (MRNA) and Aligos Therapeutics (ALGS)
Aligos Therapeutics presents data from ALG-000184 at EASL
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024